Across TCGA pan-cancer cohorts, ZNF85 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF85 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZNF85 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF85 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
UCEC and SKCM are the cancer types where ZNF85 Mutation most reproducibly stratifies survival.